Silvia Del Ry1, Manuela Cabiati2, Vanessa Bianchi3, Laura Caponi4, Pietro Di Cecco5, Benedetta Marchi3, Emioli Randazzo3, Chiara Caselli2, Tommaso Prescimone2, Aldo Clerico5,6, Giovanni Federico3. 1. Laboratorio di Biochimica e Biologia Molecolare, CNR Institute of Clinical Physiology, Via Giuseppe Moruzzi 1, 56124, Pisa, Italy. delry@ifc.cnr.it. 2. Laboratorio di Biochimica e Biologia Molecolare, CNR Institute of Clinical Physiology, Via Giuseppe Moruzzi 1, 56124, Pisa, Italy. 3. Sezione di Diabetologia Pediatrica, U.O. Pediatria Universitaria, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy. 4. Dipartimento di ricerca traslazionale e nuove tecnologie in medicina e chirurgia, Università di Pisa, Pisa, Italy. 5. Fondazione G. Monasterio, Pisa, Italy. 6. Scuola Superiore Sant'Anna, Pisa, Italy.
Abstract
PURPOSE: Recently, adrenomedullin (ADM) was defined as a new member of the adipokine family. ADM secreted by adipocytes, through its vasodilator and antioxidant actions, might be protective against metabolic syndrome-associated cardiovascular complications. The aim of the study was to assess plasma mid-regional (MR)-proADM levels in obese adolescents compared to normal-weight subjects and its relation with BMI, body composition and metabolic indices. METHODS: Plasma MR-proADM was measured in 32 healthy adolescents [BMI z-score (mean ± SEM) = 0.6 ± 0.09 and 0.8 ± 0.07 in females and males, respectively] and in 51 age-matched obese adolescents [BMI z-score (mean ± SEM) = 2.8 ± 0.12 and 2.9 ± 0.08 in female and males, respectively] by a time-resolved amplified cryptate emission technology assay. RESULTS: Plasma MR-proADM levels resulted significantly higher in obese than in normal-weight adolescents (MR-proADM: 0.33 ± 0.1 vs 0.40 ± 0.1 nmol/L, p < 0.0001). Using univariate analysis, we observed that MR-proADM correlated significantly with BMI z-score (p < 0.0001), fat mass (p < 0.0001), circulating insulin (p < 0.004), HOMA-IR (p < 0.005), total cholesterol (p < 0.03) and LDL-cholesterol (p < 0.05). Including MR-proADM as response variable and its significant correlates into a multiple regression analysis, we observed that fat mass (p = 0.014) and BMI z-score (p = 0.036) were independent determinants of circulating MR-proADM. CONCLUSIONS: Our study shows for the first time that obese adolescents have higher circulating levels of MR-proADM compared with normal-weight, appropriate controls suggesting its important involvement in obese patients.
PURPOSE: Recently, adrenomedullin (ADM) was defined as a new member of the adipokine family. ADM secreted by adipocytes, through its vasodilator and antioxidant actions, might be protective against metabolic syndrome-associated cardiovascular complications. The aim of the study was to assess plasma mid-regional (MR)-proADM levels in obese adolescents compared to normal-weight subjects and its relation with BMI, body composition and metabolic indices. METHODS: Plasma MR-proADM was measured in 32 healthy adolescents [BMI z-score (mean ± SEM) = 0.6 ± 0.09 and 0.8 ± 0.07 in females and males, respectively] and in 51 age-matched obese adolescents [BMI z-score (mean ± SEM) = 2.8 ± 0.12 and 2.9 ± 0.08 in female and males, respectively] by a time-resolved amplified cryptate emission technology assay. RESULTS: Plasma MR-proADM levels resulted significantly higher in obese than in normal-weight adolescents (MR-proADM: 0.33 ± 0.1 vs 0.40 ± 0.1 nmol/L, p < 0.0001). Using univariate analysis, we observed that MR-proADM correlated significantly with BMI z-score (p < 0.0001), fat mass (p < 0.0001), circulating insulin (p < 0.004), HOMA-IR (p < 0.005), total cholesterol (p < 0.03) and LDL-cholesterol (p < 0.05). Including MR-proADM as response variable and its significant correlates into a multiple regression analysis, we observed that fat mass (p = 0.014) and BMI z-score (p = 0.036) were independent determinants of circulating MR-proADM. CONCLUSIONS: Our study shows for the first time that obese adolescents have higher circulating levels of MR-proADM compared with normal-weight, appropriate controls suggesting its important involvement in obesepatients.
Authors: T Ishimitsu; T Nishikimi; Y Saito; K Kitamura; T Eto; K Kangawa; H Matsuo; T Omae; H Matsuoka Journal: J Clin Invest Date: 1994-11 Impact factor: 14.808
Authors: Amiram Nir; Angelika Lindinger; Manfred Rauh; Benjamin Bar-Oz; Stephanie Laer; Lynn Schwachtgen; Andreas Koch; Jan Falkenberg; Thomas S Mir Journal: Pediatr Cardiol Date: 2008-07-04 Impact factor: 1.655
Authors: H Takahashi; T X Watanabe; M Nishimura; T Nakanishi; M Sakamoto; M Yoshimura; Y Komiyama; M Masuda; T Murakami Journal: Am J Hypertens Date: 1994-05 Impact factor: 2.689
Authors: Christina Gar; Barbara Thorand; Christian Herder; Chaterina Sujana; Margit Heier; Christa Meisinger; Annette Peters; Wolfgang Koenig; Wolfgang Rathmann; Michael Roden; Michael Stumvoll; Haifa Maalmi; Thomas Meitinger; Holger Then; Jochen Seissler; Cornelia Then Journal: PLoS One Date: 2022-01-06 Impact factor: 3.240
Authors: Jacqueline Lammert; Maryam Basrai; Joachim Struck; Oliver Hartmann; Christoph Engel; Stephan C Bischoff; Anika Berling-Ernst; Martin Halle; Marion Kiechle; Sabine Grill Journal: Geburtshilfe Frauenheilkd Date: 2022-06-03 Impact factor: 2.754